Analyst Group writes in a comment on Chordate Medical’s Q2 report that the company’s chosen strategy in the UK, which is now also being implemented in Germany and Israel, could result in a faster expansion.
“As we have previously written, we believe that Chordate’s chosen strategy in the UK could result in a faster expansion in the market, which would thus also be reflected in Chordate’s sales figures. We therefore view positively that the company has chosen to apply this strategy in Israel and Germany as well.”
Analyst Group also comments on the subgroup results that will be presented at the Migraine Trust International Symposium 2022 in London on September 8th.
“The subgroup results that will be presented next week could be a real value driver in Chordate’s share, given that the results are good. This as the results would constitute direct support for the company’s marketing of, and sales targets for, the K.O.S treatment for patients with chronic migraine. This is therefore something an investor should monitor.”
Read the full analyst commentary (in Swedish)